Cargando…

Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma

The main objectives of the current study were to evaluate the efficacy and safety of a CEOP-E regimen for patients with aggressive non-Hodgkin's lymphoma (NHL). Fifty-one consecutive patients with newly diagnosed aggressive NHL were enrolled in the study. Median age of patients was 57 (range, 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jong Gwang, Sohn, Sang Kyun, Kim, Dong Hwan, Baek, Jin Ho, Park, Tae In, Lee, Kyu Bo
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2004
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816291/ https://www.ncbi.nlm.nih.gov/pubmed/15608392 http://dx.doi.org/10.3346/jkms.2004.19.6.820

Ejemplares similares

Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
por: Cherukuri, Sundar V, et al.
Publicado: (2021)

Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy
por: Matsukawa, Toshihiro, et al.
Publicado: (2018)

CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function
por: Thakar, Keyur, et al.
Publicado: (2014)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Altered Regional Brain Glucose Metabolism in Diffuse Large B-Cell Lymphoma Patients Treated With Cyclophosphamide, Epirubicin, Vincristine, and Prednisone: An Fluorodeoxyglucose Positron Emission Tomography Study of 205 Cases
por: Hu, Yuxiao, et al.
Publicado: (2022)

Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy Regimen
por: Kaur, Anahat, et al.
Publicado: (2019)

Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
por: Go, Se‐Il, et al.
Publicado: (2016)

High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.
por: Pronzato, P., et al.
Publicado: (1998)

Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study
por: Wei, Chong, et al.
Publicado: (2023)

Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin’s lymphoma: A systematic review and meta-analysis
por: Lu, Bin, et al.
Publicado: (2022)

Combination Chemotherapy with Cyclophosphamide, Vincristine, Cisplatin and Etoposide(COPE) Combined with Radiotherapy for Small Cell Lung Cancer
por: Nam, Yong Jin, et al.
Publicado: (1995)

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
por: Johnston, Patrick B., et al.
Publicado: (2021)

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
por: Lee, Eun Ju, et al.
Publicado: (2014)

Acute and Persistent Remission of Aggressive Natural Killer Cell Leukemia in an Older Patient Induced by Chidamide Combined with Cyclophosphamide, Vindesine, Prednisone, and Etoposide Therapy
por: Lin, Qingqing, et al.
Publicado: (2023)

Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
por: van Keep, Marjolijn, et al.
Publicado: (2016)

Primary diffuse large B-cell lymphoma of the bone marrow in a frail and elderly patient successfully treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
por: Niscola, Pasquale, et al.
Publicado: (2013)

Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
por: Song, Guoqi, et al.
Publicado: (2016)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
por: Lugtenburg, Pieternella, et al.
Publicado: (2017)

Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing’s and other Small Round Cell Sarcomas
por: Whelan, Jeremy, et al.
Publicado: (2012)

Intra-patient dose escalation in Ewing’s sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review
por: Lewin, Jeremy, et al.
Publicado: (2013)

CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial
por: Cai, Ming-Ci, et al.
Publicado: (2020)

The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
por: Feng, Xiaomeng, et al.
Publicado: (2021)

Successful treatment of a high-risk nonseminomatous germ cell tumor using etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine: A case report
por: Yun, Jina, et al.
Publicado: (2020)

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
por: Al-Sarayfi, Diana, et al.
Publicado: (2022)

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008)

Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial
por: Seo, Jeongkuk, et al.
Publicado: (2017)

Serum human chorionic gonadotropin ratios for the detection of etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance in high‐risk gestational trophoblastic neoplasia
por: Sirimusika, Nathapol, et al.
Publicado: (2022)

Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy
por: Lee, Seul, et al.
Publicado: (2017)

Unusual Manifestations of Vincristine Neuropathy: Report of Two Cases of Hodgkin Lymphoma
por: Akay, Olga Meltem, et al.
Publicado: (2014)

Effect of alternating combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in the peripheral blood.
por: Shimizu, E., et al.
Publicado: (1993)

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Kyoung Ha, et al.
Publicado: (2023)

Cyclophosphamide/prednisone: Various infections: case report
Publicado: (2021)

Cyclophosphamide/methylprednisolone/prednisone: No improvement: case report
Publicado: (2022)

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis
por: Yoon, Sang Eun, et al.
Publicado: (2020)

Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vincristine, and prednisone
por: Huang, Yue-Hua, et al.
Publicado: (2019)

Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients
por: Choi, Jung Yoon, et al.
Publicado: (2020)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e0kso2i9squ8bonhql48f3de57